Proprietary AI Platform for Computational Enzyme & Protein Design
Zymos-AI executes iterative AI-driven computational design and screening workflows to explore early-stage molecular candidates — supporting internal product development, licensing, and partner research projects.
Zymos-AI is a proprietary computational platform developed by Cestrum Smart Technology Corp. for AI-driven enzyme and protein design. It is not a service catalogue or a results-guarantee framework — it is a research and development technology built to explore candidate space intelligently.
The platform applies reaction-aware machine learning models to iteratively generate, score, and rank enzyme and protein candidates against defined molecular targets. Depending on target complexity, a single design project may execute dozens to over one hundred computational design and screening iterations before producing a ranked candidate data package.
The output of each project is a structured technical package containing generated candidates, computational scores, structural indicators, and interpretation notes — intended to inform downstream research decisions, not to substitute for them.
Zymos-AI generates computational candidates and supporting data. It does not guarantee biological activity, successful wet-lab expression, or downstream validation outcomes. All projects are conducted as experimental early-stage R&D.
Five integrated computational capabilities that together define the platform's approach to AI-driven enzyme and protein candidate exploration.
Iterative AI-driven generation of enzyme and protein candidates within defined target and reaction constraints, producing diverse structural families for evaluation.
Automated multi-pass screening against target criteria, filtering large candidate sets down to higher-confidence molecular candidates for further analysis.
Structured technical outputs including candidate sequences, computational scores, structural indicators, and ranked shortlists to support research decision-making.
Design logic informed by target reaction type, substrate context, and known mechanistic constraints — not purely sequence-level prediction.
Workflows scale from focused single-target studies to broader candidate family exploration across multiple application domains without architectural changes.
Computational Design Workflow
Target reaction, substrate profile, and functional constraints are encoded as design parameters for the AI engine.
The platform executes iterative candidate generation using reaction-aware models, producing diverse structural candidates per cycle.
Candidates are scored and filtered across multiple computational metrics, with weaker candidates eliminated across successive iterations.
A structured technical output is produced containing ranked candidates, scores, structural indicators, and research interpretation notes.
Zymos-AI is designed around application-agnostic computational infrastructure. These represent exploratory domains where enzyme and protein design may have scientific or industrial relevance — not confirmed deployment areas.
Computational exploration of enzyme candidates relevant to bioprocessing, biosynthesis, and biocatalysis research programs.
Early-stage candidate generation for enzyme targets with potential relevance to drug synthesis intermediates and therapeutic pathways.
Exploration of enzyme candidates for potential application in bioremediation, pollutant degradation, and environmental bioprocessing.
Computational candidate discovery targeting industrial-relevant reactions, process catalysis, and manufacturing biocatalyst applications.
Early-stage exploration of enzyme-driven molecular pathways for bio-based material synthesis and circular chemistry applications.
Zymos-AI operates as a proprietary technology platform — not a conventional service provider. Commercial engagement follows three distinct pathways depending on project type, application domain, and partner objectives.
Cestrum Smart Technology Corp. uses Zymos-AI to generate and evaluate proprietary enzyme and protein candidates across multiple application domains. Selected candidates are developed as internal intellectual property for future commercialization or licensing.
Selected computational outputs, candidate families, and application-specific discoveries may be made available for licensing to research organizations, biotech companies, and industry partners seeking access to early-stage molecular IP without engaging in full computational projects.
Zymos-AI selectively engages in defined partner research projects for custom computational enzyme and protein design workflows. Engagements produce ranked candidate data packages. No biological activity, wet-lab success, or validation outcome is guaranteed. These are experimental early-stage R&D collaborations.
Zymos-AI is an evolving platform. We engage with organizations that bring scientific depth, application focus, or strategic alignment — and where computational enzyme and protein design can meaningfully contribute to their research or development agenda.
We welcome structured conversations with partners who have a defined scientific or commercial interest in computational enzyme and protein design. Initial inquiries should include a brief description of target application domain, research context, and intended collaboration type.
We engage with organizations pursuing scientifically meaningful or commercially strategic molecular discovery initiatives. Initial inquiries are welcome regarding research collaboration, candidate licensing, or custom computational design projects. All engagements are treated as early-stage R&D partnerships.